TSHA
Taysha Gene Therapies IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.64B
P/E Ratio
—
EPS
$-0.38
Beta
1.18
52W High
$7.30
52W Low
$2.25
50-Day MA
$5.83
200-Day MA
$4.82
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas.
Fundamentals
| Revenue (TTM) | $7.47M |
| Gross Profit (TTM) | $7.47M |
| EBITDA | $-131.41M |
| Operating Margin | -1774.00% |
| Return on Equity | -97.30% |
| Return on Assets | -37.80% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $0.87 |
| Price-to-Book | 7.55 |
| Price-to-Sales (TTM) | 219.63 |
| EV/Revenue | 186.4 |
| EV/EBITDA | -0.61 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 171.30% |
| Shares Outstanding | $287.36M |
| Float | $196.74M |
| % Insiders | 10.65% |
| % Institutions | 95.75% |
Historical Volatility
HV 10-Day
61.16%
HV 20-Day
65.21%
HV 30-Day
61.11%
HV 60-Day
84.57%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($12.23 target)
3
Strong Buy10
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026